

ORIGINAL ARTICLE

# Study of Bacteria Causing Septicemia in Neonatal Intensive Care Unit

<sup>1</sup>Hussien El-Shiekh, <sup>2</sup>MahaGaafar, <sup>1</sup>Mohamed Yosri, <sup>2</sup>Dina Hassan\*,  
<sup>1</sup>Hassan Said.

<sup>1</sup>Botany and Microbiology Department, Faculty of Science, El-Azhar University, Egypt  
Regional Center of Mycology and Biotechnology El-Azhar University, Egypt

<sup>2</sup>Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Egypt

## ABSTRACT

### Key words:

Neonatal septicemia,  
bacterial agents, antibiotic  
susceptibility, ESBL-  
producing organism

**Background:** Septicemia continues to be a major cause of neonatal morbidity and mortality worldwide. Blood culture is the gold standard for diagnosis of septicemia. **Objectives:** To determine the common causative bacterial agents of neonatal sepsis and their antimicrobial susceptibility in NICU. **Methodology:** Five hundred and fifty one suspected cases of septicemia who were admitted to the Neonatal Intensive Care Unit (NICU) of Abu El Rich El Mounira pediatric Hospital from 1st January 2013 to 31<sup>ST</sup> December 2013 were included. Blood cultures were withdrawn for all cases. Organisms were isolated and identified by conventional biochemical reactions and sensitivity was tested by Kirby Bauer disc diffusion technique. Also screening for Extended Spectrum B lactamase (ESBL) producing bacteria was done. **Results:** Blood Culture was positive in 87(15.7%) of cases. There was a predominance of Gram negative organisms (58.6%) over Gram positive organisms (36.8%) and Fungi (4.6%). Gram negative bacteria showed high susceptibility to impenem and merpenem and reduced susceptibility to ampicillin and ampicillin-sulbactam, while Gram positive bacteria were sensitive to vancomycin and rifampicin and had reduced susceptibility to ampicillin. ESBL Production was found in 37.3% of Gram negative strains. Thirty one isolated pathogens were found to be hospital acquired, of which 64.5% were Gram Negative while 32.3% were Gram positive represented 32.3% and fungi 3.2% were fungi. **Conclusions:** Neonatal sepsis in our NICU is mainly caused by Gram negative organisms, which are developing resistance to commonly used antibiotics. This emphasizes the need to implement infection control policies at the hospital level for effective management of spread ESBL producing organisms and Multidrug resistance.

## INTRODUCTION

Globally, sepsis is still one of the major causes of morbidity and mortality in neonates, in spite of recent advances in health care units<sup>1</sup>. More than 40% of under-five deaths globally occur in the neonatal period, resulting in 3.1 million newborn deaths each year<sup>2</sup>. The majority of these deaths usually occur in low-income countries and almost 1 million of these deaths are attributed to infectious causes including neonatal sepsis meningitis, and pneumonia<sup>3</sup>. On the other hand, the survivors of neonatal sepsis are vulnerable to short and long-term neurodevelopmental morbidity<sup>4</sup>.

Neonatal sepsis is defined as a clinical syndrome in an infant 28 days of life or younger, manifested by systemic signs of infection and isolation of a bacterial pathogen from the bloodstream<sup>5</sup>. Diagnosis and management of sepsis are a great challenge facing neonatologists in NICUs. Clinical diagnosis of presentation is difficult due to nonspecific signs and symptoms. In addition, laboratory diagnosis is time consuming. This matter necessitates the initiation of empirical antibiotic therapy till the suspected sepsis is ruled out. At the same time, increased multidrug resistant organisms make the treatment options fewer and the effective treatment is delayed<sup>6</sup>.

Neonatal sepsis is caused by Gram-positive and Gram negative bacteria and *Candida*<sup>7</sup>. The diversity of organisms causing sepsis varies from region to another and changes overtime even in the same place<sup>8</sup>.

This is attributed to the changing pattern of antibiotic use and changes in lifestyle. Many factors

### \*Corresponding author:

Dina Mohammed Hassan MD.  
Lecturer of Clinical and Chemical Pathology,  
Faculty of Medicine-Cairo University, Cairo, Egypt.  
Email: [dinamhassan@kasralainy.edu.eg](mailto:dinamhassan@kasralainy.edu.eg), Tel: 01006911788

contribute to the susceptibility of the neonate to sepsis, which can influence the incidence of neonatal sepsis. Incidence also varies from nursery to nursery depending on conditions predisposing infants to infection<sup>7</sup>.

In neonatal intensive care units (NICUs), hospital acquired infections represent a significant problem and their rates appear to be increasing, especially because of the longer survival of very low birth weight infants, the growing complexity of invasive treatments and more children are hospitalized for longer periods<sup>9</sup>.

The findings of the study have important implications for community-based research and programs to improve maternal and neonatal health and survival not only in Egypt, but also in other similar developing world settings.

## METHODOLOGY

- 1. Study design:** A cross sectional study was conducted in our study including 551 suspected cases of septicemia admitted to Neonatal Intensive Care Unit (NICU) of the of Abu Rich El Monira pediatric Hospital in Egypt from the 1st of January , 2013 to 31<sup>st</sup> of December, 2013.
- 2. Isolation of bacteria:** A blood sample of 0.5 to 1.0 ml was withdrawn aseptically after the venipuncture site was wiped with 70% alcohol followed by two cycles of 2 min of disinfection with povidone-iodine, then inoculated into BACTEC pediatric blood culture bottles (BD Diagnostic Systems). Bottles were transported to the laboratory as soon as possible and immediately incubated in the instrumented Blood Culture Systems which is BD BACTEC™ 9050. Blood cultures were processed using the standard technique described by Cruickshank et al<sup>10</sup> and were cultured on specific culture media to isolate the causative organisms. Identification of the recovered bacteria was done by colony characteristics, Gram staining and biochemical tests. For Gram positive organisms identification was done by Catalase and Coagulase test. For Gram negative organisms, identification was done by biochemical reactions as Simon's Citrate test, MIO (Motility, Indole, Ornithin), TSI (Triple Sugar Iron) and Urease Tests. Regarding Candida isolates confirmation was done by subculture on Sabouraud dextrose agar media and germ tube was done for differentiation between candida albicans and non albicans<sup>11</sup>.
- 3. Confirmation of Gram Negative isolates by API strips:** The identification of the 51 Gram negative bacterial isolates was performed using API strips inoculated and incubated as described by the manufacturer (bio Merieux Vitek System, France). The strips were API 10S, API 20 NE and API 20E. Examination of the strips was conducted after 18-23 h, and the results from the 24 h analysis were used. The results were read and analyzed using analytical profile index.
- 4. Antimicrobial Susceptibility testing:** Antimicrobial susceptibility testing was performed for all blood culture isolates by Kirby-Bauer disc diffusion method as recommended in the Clinical Laboratory Standards Institute (CLSI 2012) guidelines<sup>12</sup>.
- 5. Phenotypic confirmatory test for ESBL production by Gram Negative isolates:**
  - a. Double disk synergy test (DDST)** was performed using disks of 30 µg each of cefpodoxime (CPD), ceftazidime (CAZ), cefotaxime (CTX), ceftriaxone (CRO), aztreonam (ATM) (Oxoid Co. England) along with AMC (amoxicillin 20µg and clavulenic acid 10 µg). The disks were placed at the distance 20 mm from each other (centre to centre) and incubated at 37°C overnight. A clearly visible extension of the edge of the inhibition zone of any disk towards the amoxicillin clavulenic disk was interpreted as positive for Clavulenic acid (CLA) synergy<sup>13</sup>.
  - b. Cephalosporin/clavulanate combination discs:** A 0.5 MacCfurland suspension of the isolate is inoculated into a 10-mm Müller Hinton agar plate using the antimicrobial discs ceftazidime (30 µg), ceftazidime /clavulenic acid (30/10 µg). After incubation, the zone of inhibition around each of the discs is measured. An increase of > 5 mm in zone diameter for either antimicrobial agent tested in combination with clavulenic acid versus its zone when tested alone indicates positive for Extended Spectrum Beta Lactamase (ESBL) production<sup>14</sup>.
- 6. Statistical Analysis:** Summary of measures was reported as mean and standard deviation (SD) for quantitative variables and percentages for categorical variables. The differences in distribution were evaluated using the chi-square test for categorical variables. Value ≤ 0.05 was considered statistically significant. All the statistical analyses were performed using computer programs SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) version 15 for Microsoft Windows.

## RESULTS

During the period of study 551 blood culture bottles were received in the lab from which 87(15.7%) were positive. Forty six (52.8%) of the isolates were from male patients and 41(47.2%) were from female patients resulting in an overall male to female ratio of 1.3: 1. However, no significant difference was detected regarding sex ( $P > 0.05$ ).

Distributions of pathogens isolated from blood culture of infants involved in the current study are presented in table 1. There was a predominance of Gram negative organisms 51(58.6%) over Gram positive organisms 32(36.8%) and fungi 4(4.6%). *Klebsiella pneumoniae* was the most frequently isolated organism 27 (31.0%), followed by *Coagulase Negative Staphylococcus* (CoNS) 19 (21.8%), *Staphylococcus aureus* 11(12.6%), *E.coli* 8 (9.2%). *Pseudomonas aeruginosa* 8(9.2%), other less frequently isolated organisms were *Acinetobacter spp.* 4 (4.6%), *Candida spp.* 4 (4.5%), *Enterobacter aeruginosa*3 (3.4%), *Streptococcus Pneumonia*1 (1.5%), *Streptococcus Viridans*1 (1.5%), *Salmonella typhi*1 (1.5%)

**Table 1: Distribution of isolated pathogens causing septicemia.**

Type of organism	N(%)
<b>Gram Negative Bacteria</b>	51(58.6)
<i>Klebsiella pneumoniae</i>	27(31.0)
<i>E.coli</i>	8(9.2)
<i>Enterobacter aeruginosa</i>	3(3.4)
<i>Salmonella typhi</i>	1(1.5)
<i>Pseudomonas aeruginosa</i>	8(9.2)
<i>Acinetobacter spp.</i>	4(4.5)
<b>Gram Positive Bacteria</b>	32(35.6)
<i>Staphylococcus aureus.</i>	11(12.6)
<i>Coagulase Negative staphylococcus</i>	19(21.8)
<i>Streptococcus Pneumonia</i>	1(1.5)
<i>Streptococcus Viridans</i>	1(1.5)
<b>Fungi</b>	4(4.5)
<i>Candida spp.</i>	4(4.5)
<b>Total</b>	87(100.0)

N: Number

The resistance of Gram-negative organisms to the most relevant antibiotics is described in table 2.

*Klebsiella pneumonia* which is the most common isolated Gram negative isolate showed 96.4% reduced susceptibility to ampicillin, 82.2% to ampicillin+sulbactam, 71.5% to amoxicillin-clavulenic, third generation cephalosporins (ceftriaxone 89.3%, cefatizidime 85.7%) fourth generation cephalosporins (cefepime 82.2%). They showed also reduced susceptibility 44.4% to levofloxacin, 44.4% to cefoxitin, 37.0% to ciprofloxacin, 37.0% to amikacin, They were highly susceptible to imipenem by 74.0%, to meropenem by 67.8%, and sulphameth-trimeth by 67.8%.

*E.coli* showed 87.5% reduced susceptibility to ampicillin, 87.5% to ampicillin+sulbactam, 62.5% to amoxicillin-clavulanic, 62.5% to cefoxitin, third generation cephalosporins (ceftriaxone 75.0%, cefatizidime 87.5%) fourth generation cephalosporins (cefepime 62.5%). They showed also reduced susceptibility 50.0% to Levofloxacin, 62.5% to ciprofloxacin, 62.5% to amikacin. They were susceptible to imipenem by 87.5%, meropenem by 75.0% and sulphameth-trimeth by 75.0%.

The resistance of Gram-positive organisms to the tested antibiotics is presented in table 3.

*Coagulase negative Staphylococci* which is the most common isolated Gram positive bacteria showed 84.2% reduced susceptibility to ampicillin, 78.1% to erythromycin, They showed also reduced susceptibility 63.2% to sulphameth-Trimeth, 57.8% to doxycyclin, 52.6% to clindamycin, 42.1% to chloramphenicol, 42.1% to gentamycin, 36.8% to Amoxicillin-clavulenic, 36.8% to azithromycin, and 31.6% to cefoxitin. They were all susceptible to vancomycin 100%, and 68.4% to rifampicin.

*Staphylococcus aureus* showed 100% reduced susceptibility to ampicillin, 81.8% to amoxicillin-clavulenic, 72.8% to sulphameth-trimeth, 72.8% to azithromycin, and 72.8% to chloramphenicol. They showed also reduced susceptibility to erythromycin 54.5%, doxycyclin 54.5%, clindamycin 45.5%, cefoxitin 36.4%, They were all susceptible to vancomycin 100%, and 63.6% were susceptible to rifampicin.

**Table 2: Reduced susceptibility pattern of the isolated Gram Negative organisms to different antibiotics**

Antibiotic	<i>Klebsiella pneumoniae</i>		<i>E.coli</i>		<i>Pseudomonas aeruginosa</i>		<i>Acinetobacter spp.</i>		<i>Enterobacter spp.</i>		Total	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Ampicillin	26	96.4	7	87.5	7	87.5	4	100.0	3	100	47	92.2
Amoxicillin-clavulenic	19	71.5	5	62.5	5	62.5	4	100.0	1	33.3	34	66.6
Ampicillin+Sulbactam	22	82.2	7	87.5	7	87.5	4	100.0	2	66.6	42	82.3
Impenem	7	25.9	1	12.5	2	25.0	1	25.0	0	0.00	11	21.6
Cefoxitin	15	55.6	5	62.5	7	87.5	4	100.0	2	66.6	33	64.7
Ceftriaxone	24	89.3	6	75.0	8	100.0	4	100.0	3	100.0	45	88.2
Cefatizidime	23	85.7	7	87.5	8	100.0	4	100.0	2	66.6	44	86.2
Cefepime	22	82.2	5	62.5	7	87.5	4	100.0	2	66.6	41	80.4
Amikacin	17	63.0	3	37.5	6	75.0	3	75.0	1	33.3	30	58.8
Sulphameth-Trimeth	8	32.2	2	25.0	6	75.0	3	75.0	1	33.3	20	39.2
Merpenem	8	32.2	2	25.0	4	50.0	1	25.0	0	0.00	15	29.5
Ciprofloxacin	17	63.0	3	37.5	3	37.5	2	50.0	0	0.00	25	49.0
Levofloxacin	15	55.6	4	50.0	2	25.0	3	75.0	0	0.00	24	47.1

% was correlated to the total number of each bacterial species.

**Table 3: Reduced susceptibility pattern of the isolated Gram positive organisms to different antibiotics.**

Antibiotic	<i>Coagulase Negative staphylococcus</i>		<i>Staphylococcus aureus</i>		<i>Streptococcus sp.</i>		Total	
	No.	%	No.	%	No.	%	No.	%
Ampicillin	11	100.0	16	84.2	1	50.0	28	87.5
Vancomycin	0	0.00	0	0.00	0	0.00	0	0.00
Amoxicillin-clavulenic	9	81.8	12	63.1	0	0.00	21	65.6
Rifampicin	4	36.4	6	31.6	0	0.00	10	31.2
Cefoxitin	7	63.6	13	68.4	-	-	20	62.5
Gentamycin	6	54.5	11	57.9	2	100.0	19	59.3
Clindamycin	6	54.5	9	47.4	1	50.0	16	50.0
Erythromycin	5	45.5	15	78.9	2	100.0	22	68.7
Sulphameth-Trimeth	8	72.8	7	36.8	-	-	15	46.8
Doxycyclin	5	45.5	8	42.2	-	-	13	40.6
Chloramphenicol	8	72.8	11	57.9	2	100.0	21	65.6
Azithromycin	8	72.8	12	63.2	-	-	22	68.7

% was correlated to the total number of each bacterial species

#### Hospital acquired pathogens:

Thirty one isolated pathogens were found to be hospital acquired, of which Gram Negative Bacteria were found to be the predominant isolates representing 64.5%, while Gram positive bacteria represented 32.3% and fungi represented 3.2% of isolates.

In the present study total of 19(37.3%) Gram negative strains were positive for ESBL Production, ESBL was detected in 9 (47.4 %) isolates of *Klebsiella pneumoniae*, 6 (31.6 %) isolates of *E. coli*, 3 (15.8 %)

isolates of *Pseudomonas aeruginosa*, 1 (5.3 %) isolates of *Enterobacter spp.* and in none of the isolates of *Acinetobacter spp.* and *Salmonella typhi*. Sixteen (84.2%) of ESBL positive isolates by DDST were positive by combined disc method, also 3 of ESBL negative isolates by DDST were positive by combined disc method and 32 of ESBL negative isolates by DDST were negative by combined disc method. DDST is in agreement with combined disc method for detection of ESBL positive cases this result showed in table 4 and 5.

**Table 4: Relation between combined disc and double disc synergy test in detection of ESBL.**

		Double disc synergy (DDST)		Total	Kappa
		+ve	-ve		
Combined disc	+ve	16	3	19	0.8
		84.2%	15.8%	100.0%	
	-ve	0	19	19	
		0.0%	100.0%	100.0%	

**Table 5: Sensitivity and specificity of double disc synergy test compared to combined disc.**

Item	TP	FN	TN	FP	Sens.	Spec.	Accuracy
DDST	14	2	16	0	87.5%	100.0%	87.5%

## DISCUSSION

Neonatal sepsis is the commonest cause of neonatal morbidity and mortality worldwide. In the World Health Organization 2000–2003 report, neonatal sepsis and pneumonia were responsible for about 1.6 million deaths each year, mainly in resource-poor countries<sup>15</sup>. In this study, documented neonatal sepsis with positive culture was 15.7%. This is low compared to about 20% yield reported by Baltimore and Gladstone<sup>16</sup> and higher than previous studies done by Begum et al.<sup>12</sup> where positive cases were 13.0%<sup>17</sup>. Much higher rates of 45.9% was also described by Eman et al.<sup>18</sup>. These varying proportions may be due to the difference in methodology used and the areas of study, as regional variation are known to occur.

The organisms causing neonatal septicemia differ from area to area and also change with respect to time, even in the same area, which may be due to different living conditions<sup>19</sup>. Our study showed that the Gram negative bacteria constituted the major group of isolates (58.6%) of neonatal septicemia cases compared to (36.8%) Gram Positive bacteria and (4.6%) *Candida*. This finding is similar to that of another study which showed that Gram negative bacteria were responsible in most cases of neonatal sepsis<sup>20</sup>. Other authors in other studies reported Gram positive bacteria as the commonest cause of neonatal sepsis<sup>21,22</sup>.

*Candida* spp. were isolated only in 4 cases (4.6%), similar findings were found in other studies done by Kavitha et al in year 2014 where *Candida* isolates represented (5.05%)<sup>23</sup> and Eman et al<sup>18</sup> it represented (2.86%)<sup>18</sup> but this was lower than several other reports showing frequency of isolation of 13.6–19.6% of cases<sup>24</sup>.

In this study, the most frequent isolate was *Klebsiella pneumoniae* 27 (31.0%). This was in accordance with other studies<sup>25, 26</sup>. The pattern of isolated organisms in our study slightly differs from the findings in Iran<sup>27</sup>, where *Pseudomonas aeruginosa* was the most common cause of neonatal sepsis followed by *Klebsiella* spp. and *E. coli*. In a similar study from

Bangladesh, Nepal and Pakistan, *E. coli* was the leading cause of neonatal sepsis followed by *Klebsiella* spp.<sup>28</sup>.

In our study, *Coagulase Negative Staphylococcus* was the second most common isolated organism, similar results where CoNS had been reported as the most common organism from blood culture isolates were found<sup>29,30</sup>. In the present study 21.8% of isolates were CoNS. The clinical significance of CoNS when isolated from blood cultures should be always evaluated. Some studies have reported that up to 85% of CoNS representing contamination rather than true bacteremia<sup>31</sup>. However, CoNS have become an important nosocomial pathogen partly because of the increasing use of medical devices such as long term indwelling catheters, vascular grafts, and prosthetic heart valves and joints<sup>32</sup>. On the other hand Mustafa and Ahmed in year 2014 reported in their study *Staphylococcus aureus* as the most common causative agent of neonatal bacteremia<sup>25</sup>.

The problem of antimicrobial resistance is highlighted by the World Health Organization (WHO) and combating antimicrobial resistance has been selected as the theme for World Health Day<sup>33</sup>. In this study, *Klebsiella pneumoniae* isolates were found to be highly resistant to routinely used antibiotics, followed by *Pseudomonas aeruginosa* and *Escherichia coli*. All Gram negative isolates were having considerable sensitivity to amikacin, levofloxacin and ciprofloxacin but were highly susceptible to imipenem (74.4%) and meropenem (70.5%) and highly resistant to ampicillin, amoxicillin-clavulanic acid, cefotaxime, ceftriaxone, ceftazidime, cefepime. Aurangzeb et al. reported considerable resistance of Gram negative bacteria to commonly used antibiotics such as ampicillin, amoxicillin, ceftazidime, cefotaxime and comparatively low resistance to gentamicin, imipenem and ciprofloxacin<sup>34</sup>.

In our study, only two isolates of *Pseudomonas aeruginosa* were recovered from blood cultures exhibiting resistance to all antibiotics tested. This result is in accordance with another study done in Egypt<sup>18</sup>.

Among the Gram-Positive isolates, all isolates were highly resistant to ampicillin, amoxicillin-clavulanic acid, erythromycin, azithromycin and chloramphenicol but all isolates were highly susceptible to vancomycin (100%) and rifampicin (67.7%).

In our study, all CoNS isolates showed high resistance to ampicillin and cefoxitin, erythromycin, azithromycin, and gentamicin. These results are in agreement with a previous study.<sup>18</sup>

Interestingly, all staphylococcal isolates were sensitive to Vancomycin as previously found in other reports<sup>35</sup> but its overprescription may result in the development of vancomycin-resistant strains such as enterococci.

According to our finding, best sensitivity among Gram negative isolates was observed with imipenem followed by meropenem while among Gram-positive isolates was with vancomycin and is followed by rifampicin. The high resistance rates found in this study may be associated with the frequent use of antimicrobial drugs for both prophylactic and therapeutic treatment of hospitalized newborns<sup>36</sup>. In view of the above facts the strategy of antibiotic usage in neonates should be reviewed periodically even in the same hospital.

In our study a NICU hospital acquired infection rate of 35.6% was reported. A wide variations in the reported incidence of hospital acquired infection rates in literature according to the NICUs, as in the United States, hospital acquired infection rates vary from 6 to greater than 40%<sup>37</sup>, and in one study the incidence has been reported to be as high as 70%<sup>38</sup>. This discrepancy in hospital acquired infection rates could be not only attributed to the infection control policies and the Surveillance system in every place, but also due to differences in defining, identifying and reporting hospital acquired infection as there are differences in reporting it, particularly the time of onset.

The present study showed that 37.3% of Gram negative strains isolated from blood specimens were ESBL producers. This high prevalence is related to the less controlled use of antibiotics in Egypt, where many drugs are still available over the counter. Few studies have investigated the prevalence of ESBL in Egyptian hospitals. Abdallah et al in year 2015 detected 48.9% ESBL-producing *Enterobacteriaceae* among strains isolated from patients in the intensive care unit at El-Ahrar General Hospital, Zagazig, Egypt<sup>39</sup>. While Bouchillon et al conducted the PEARLS study in 2001–2002, and found that 38.5% of *Enterobacteriaceae* isolates did produce an ESBL resistance<sup>40</sup>. A lower ESBL prevalence rate (16%) was found among 120 isolates collected between May 2007 and August 2008 at the Theodor Bilharz Research Institute, Cairo, Egypt<sup>41</sup>.

In the present study we observed that 47.4% *Klebsiella pneumoniae* and 31.6% *E. coli* isolates were ESBL producers. This is in agreement with a study conducted at Menoufia University, where ESBL producing Gram Negative Bacilli (GNB) were mostly *Klebsiella spp.* (54.3%) followed by *E. coli* (19.6%)<sup>42</sup>. In 2003, Jain et al detected ESBL in 86.6% of *Klebsiella pneumoniae* and 63.6% of *Escherichia coli*<sup>43</sup>. Also study done by Gandhi et al year 2013, ESBL production was seen in 52.9% of *Escherichia coli* and 50% of *Klebsiella pneumoniae* isolates<sup>44</sup>.

In the present study, the Double disc synergy test (DDST) was able to detect 16 out of the 19 ESBL-producers detected by the combined disc method and thus showing a substantial agreement with combined disc (Kappa=0.8) and a sensitivity of 84.2%. This finding is in agreement with Daef et al in year 2009 who reported that 21 out of 23 (91.3%) potentially ESBL-producing *Enterobacteriaceae* were positive by DDST<sup>45</sup>. The Combined disc test was previously compared with DDST and it was found to be an inexpensive alternative for the DDST, for the detection of ESBL producers. The DDST may miss few ESBL cases because of the problem of optimal disc spacing and the correct storage of the clavulenic acid containing discs. Assuming that a laboratory is currently testing the sensitivity for ceftazidime by using the disc diffusion test and it required only one disc to be added to the sensitivity plate by combined disc test and would screen all Gram negative bacteria in the diagnostic laboratory for ESBL production. This method is technically simple and inexpensive<sup>46</sup>.

The Clinical and Laboratory Standards Institute (CLSI) therefore, also recommended the use of Combined disc test for the phenotypic confirmation of the ESBL producers among *E. coli* and *K. pneumoniae*<sup>12</sup>.

## CONCLUSION

Antibiotic resistance is today a global problem. Neonatal septicemia is a life-threatening emergency, and rapid treatment with antibiotics is essential for a favorable outcome. In our study *Klebsiella pneumoniae* and *CONS* together with *Staph aureus* are the leading causative agents of neonatal sepsis in our unit. They were resistant to commonly used antibiotics, thus according to antibiotic sensitivity results, appropriate initial empirical antibiotic therapy for neonatal sepsis should be replaced. Every unit should carefully follow the bacterial spectrum and resistance patterns of microorganism responsible for neonatal infections to design a specific empirical antibiotic regimen. Appropriate infection control policies and procedure are essential to prevent spread of ESBL and multidrug resistant organisms in our NICU.

## REFERENCES

1. Wu JH, Chen CY, Tsao PN, Hsieh WS, and Chou HC. Neonatal sepsis: a 6-year analysis in a neonatal care unit in Taiwan. *Pediatrics and Neonatology*.2009; 50(3): 88–95
2. WHO .World Health Organization. Antimicrobial resistance 2011. Fact sheet number 194
3. Black RE, Cousens S, Johnson HL et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis.2010; *The Lancet* 375(9730): 1969–1987
4. Stoll BJ, Hansen N, Fanaroff A et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. *The New England Journal of Medicine*.2002; 347(4): 240–247
5. Edwards MS and Baker CJ. Sepsis in the newborn. In *Krugman's Infectious Diseases of Children*.2004; 11th ed.: 545-61
6. Patel SJ and Saiman L. Antibiotic resistance in neonatal intensive care unit pathogens: mechanisms, clinical impact, and prevention including antibiotic stewardship. *Clinics in Perinatology*.2010; 37(3): 547–563
7. Jumrah DS and Hassan MK. Predictor of mortality outcome in neonatal sepsis. *Medical Journal of Basrah University*.2007; 25: 11–18
8. Shrestha S, Adhikari N, Rai BK and Shreepaili A. Antibiotic resistance pattern of bacterial isolates in neonatal care unit. *Journal of the Nepal Medical Association*.2010; 50(4):277– 281
9. José M, Cernadas C, Silvia Fernandez Jonusaset al. Clinical outcome of neonates with nosocomial suspected sepsis treated with cefazolin or vancomycin. Non-inferiority, randomized, controlled trial *Arch Argent Pediatr*.2014; 112(4):308-314 – 308
10. Cruickshank K, Duguio JP and Marnion BP. Test for sensitivity to antimicrobial agents, In *Medical Microbiology*, Edinburgh: Churchill Livingstone.1980; 12(2), 196
11. Krieg NR. *Bergey's Manual of systematic Bacteriology*. Vol. The Williams and Wilkins Company, Library of Congress, Baltimore, USA.1984
12. Clinical and Laboratory Standard Institute .Performance standards for antimicrobial susceptibility testing; twentieth informational supplement. CLSI document M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.2012
13. Jarlier V, Nicolas M-H, Fournier G and Philippon A. Extended board-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterbacteriaceae: hospital Prevalence and susceptibility patterns. *Rev Infect Dis*.1988; 10:86-878
14. Sanders M, Fille M, Bauernfeind A, Stemplinger I and Fey P. Extended spectrum beta-Lactamase (ESBL)-producing Enterbacteriaceae Considerations for diagnosis, prevention and drug treatment. *Drugs*.1996; 63:353-365
15. Posfay-Barbe KM, Zerr DM, and Pittet D, (2008). "Infection control in paediatrics," *The Lancet Infectious Diseases*.2008;8(1):19–31
16. Baltimore RS, Huie SM, Meek JI, Schuchat A, O'Brein KL. Early-onset neonatal sepsis in the era of group B Streptococcal prevention. *Pediatrics*.2001; 108:1094-98
17. Begum M, Hassan ZS, Haque M, Jahan N, Chowdhury K, Rob A. W, (2013). Study of Bacteriological pathogen causing neonatal sepsis at NICU in Ad-din medical college hospital. *Northern International Medical College Journal*.2013;9(2): 352–365
18. Eman M. Shehab El-Din R, Mohamed M. El-Sokkary A, Mohamed R and Hassan R. Epidemiology of Neonatal Sepsis and Implicated Pathogens: A Study from Egypt: *BioMed Research International*. Volume 2015, Article ID 509484, 11 pages
19. Shrestha P, Das BK, Bhatta NK, Jha DK, Das B, Setia A, Tiwari A. Clinical and bacteriological profile of blood culture positive sepsis in newborns. *J. Nepal. Pediatr. Soc*.2007;27(2):64-67
20. Muhammad Z, Ahmed A, Hayat U, Wazir MS, Rafiyatullah, Wagas H. Neonatal sepsis Causative bacteria and their resistance to antibiotics. *J Ayub Med Coll Abbottabad* .2010;22(4):33-6
21. Li Z, Xiao Z, Zhong Q, Zhang Y, and Xu F. 116 cases of neonatal early-onset or late-onset sepsis: a single center retrospective analysis on pathogenic bacteria species distribution and antimicrobial susceptibility," *International Journal of Clinical and Experimental Medicine*.2013;6(8): 693–699
22. Ballot DE, Nana T, Sriruttan C and Cooper PA. "Bacterial bloodstream infections in neonates in a developing country," *ISRN Pediatrics*, vol. 2012, Article ID 508512, 6 pages
23. Kavitha H, Anuradha K, Venkatesha D. Comparison of Susceptibility of Various Candida Species Isolated From Neonatal Septicaemia to Voriconazole and Fluconazole: *IOSR Journal of Pharmacy and Biological Sciences*.2014; e-ISSN: 2278-3008, p-ISSN:2319-7676. 9(2): 78-81
24. Agarwal J, Bansal S, Mailk GK, Jain A. Trends in neonatal septicemia, Emergence of non-albican Candida, *Indian Pediatr*.2004; 41, 712–5
25. Mustafa M and Ahmed SL. Bacteriological profile and antibiotic susceptibility patterns in neonatal septicemia in view of emerging drug resistance: *J Med Alied Sci*.2014; 4 (1): 02-08
26. Mondol SK, Nag DR., Bandyopadhyay R, Chakraborty D and Sinha SK. Neonatal sepsis: Role of a battery of immunohematological tests in early

- diagnosis, *International Journal of Applied and Basic Medical Research*.2012;2(1), 43-47
27. Movahedian AH, Moniri R, and Mosayebi Z. "Bacterial culture of neonatal sepsis," *Iranian Journal of Public Health*.2006; 35(4): 84–89
  28. Ahmed AS, Chowdhury MA, Hoque M, Darmstadt GL. Clinical and bacteriological profile of neonatal septicemia in a tertiary level pediatric hospital in Bangladesh. *Indian Pediatr*.2002; 39(11):1034-9
  29. Dagne M, Yismaw G, Gizachew M, Gadisa A, Abebe T, Tadesse et al. Bacterial profile and antimicrobial susceptibility pattern in septicemia suspected patients attending Gondar University Hospital, Northwest Ethiopia. Dagne et al. *BMC Research Notes*. 2013;6:283
  30. Meremikwu MM, Nwachukwu CE, Asuquo AE, Okebe JU, Utsalo SJ. Bacterial isolates from blood cultures of children with suspected septicaemia in Calabar, Nigeria. *BMC Infectious Diseases*. 2005;5:110
  31. Towns ML, Quartey SM, Weinstein MB, Reimer LG, Reller LB. The clinical significance of positive blood cultures: a prospective, multicenter evaluation. In: Abstracts of the 93rd General Meeting of the American Society for Microbiology, C-232. Washington, DC: American Society for Microbiology. 1993
  32. Reimer LG, Wilson ML, Weinstein MP. Update on detection of bacteremia and fungemia. *Clin Microbiol Rev*.1997; 10:444-65
  33. WHO. World Health Organization. Antimicrobial resistance 2011. Fact sheet number 194
  34. Aurangzeb B and Hamdeed A. Neonatal sepsis in hospital born-babies: bacterial isolates and susceptibility patterns, *J Coll Physicians Surg Pak*.2003; 13(11): 629-632
  35. Shah AJ, Mulla SA, and Revdiwala SB. Neonatal sepsis: high antibiotic resistance of the bacterial pathogens in a neonatal intensive care unit of a tertiary care hospital," *Journal of Clinical Neonatology*.2012; 1(2): 72–75
  36. Loureiro MM, Moraes BA, Quadra MR et al. Study of multi-drug resistant microorganisms isolated from blood cultures of hospitalized newborns in Rio de Janeiro city, Brazil. *Brazil J Microbiol*.2002; 33(1):73-8
  37. Zafar N, Wallace CM, Kieffer P, Schroeder P, Schootman M and Hamvas A. Improving survival of vulnerable infants increases neonatal intensive care unit nosocomial infection rate. *Arch Pediatr Adolesc Med*.2001; 155: 1098-1104
  38. Hwang JH, Choi CW and Chang YS. The efficacy of clinical strategies to reduce nosocomial sepsis in extremely low birth weight infants. *J Korean Med Sci*.2005; 20: 177-181
  39. Abdallah HM, Wintermans BB, Reuland EA, Koek A, al Naiemi N, Ammar AM et al. Extended-Spectrum  $\beta$ -Lactamase- and Carbapenemase-Producing Enterobacteriaceae Isolated from Egyptian Patients with Suspected Blood Stream Infection. *PLoS ONE*.2015; 10(5): e0128120
  40. Bouchillon SK, Johnson BM, Hoban DJ, Johnson JL, Dowzicky MJ, Wu DH, et al. Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant *Enterococcus faecium* and methicillin-resistant *Staphylococcus aureus* in 38 centres from 17 countries: the PEARLS study 2001–2002. *Int J Antimicrob Agents*. 2004; 24: 119–24
  41. Fam N, Leflon-Guibout V, Fouad S, Aboul-Fadl L, Marcon E, Desouky D, et al. CTX-M-15-producing *Escherichia coli* clinical isolates in Cairo (Egypt), including isolates of clonal complex ST10 and clones ST131, ST73, and ST405 in both community and hospital settings. *Microb Drug Resist*. 2011; 17: 67–73
  42. Eissa NA, Al-Ragehy NA, Koura BA et al. ESBL producing Enterobacteriaceae and *Pseudomonas aeruginosa* causing nosocomial pneumonia in Menoufyia University. M.Sc.2007 Thesis (Microbiology), Faculty of Medicine, Cairo University, Egypt
  43. Jain A, Roy I, Gupta MK, Kummar M, Agarwal SK. Prevalence of extended – spectrum beta – lactamase- producing gram – negative bacteria in septicemic neonates in a tertiary care hospital. *J Med Microbiol*.2003; May;52(Pt):421-5
  44. Gandhi S, Ranjan KP, Ranjan N, Sapre N, Masani M. Incidence of neonatal sepsis in tertiary care hospital: an overview. *Int J Med Sci Public Health*.2013; 2(3):548–52
  45. Daef AE, Aly AS, Seif El-Din AS, et al. Phenotypic and genotypic detection of extended spectrum beta-lactamase *Klebsiella pneumoniae* isolated from Intensive Care Units in Assuit University Hospital. *Egyptian Journal of Medical Microbiology*.2009; 18: 29-40
  46. Shukla I, Tiwari R, Agarwal M. Prevalence of extended-spectrum  $\beta$ -lactamase producing *Klebsiella pneumoniae* in a tertiary care hospital. *Indian J Med Microbiol*.2004; 22(2):87-91.